Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.

Suzuki F, Kubota T, Miyazaki Y, Ishikawa K, Ebisawa M, Hirohata S, Ogura T, Mizusawa H, Imai T, Miyasaka N, Nanki T.

Arthritis Res Ther. 2012 Mar 6;14(2):R48. doi: 10.1186/ar3761.

2.

[Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].

Chen F, Shu XM, Wang DX, Xie Y, Wang GC.

Zhonghua Yi Xue Za Zhi. 2012 Aug 21;92(31):2182-5. Chinese.

PMID:
23158422
3.

KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.

Fathi M, Barbasso Helmers S, Lundberg IE.

J Intern Med. 2012 Jun;271(6):589-97. doi: 10.1111/j.1365-2796.2011.02459.x. Epub 2011 Oct 31.

4.

[Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].

Chen F, Shu XM, Wang DX, Wang GC, Lu X.

Beijing Da Xue Xue Bao. 2012 Apr 18;44(2):204-8. Chinese.

5.
6.

Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.

Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC.

J Rheumatol. 2015 Jun;42(6):979-87. doi: 10.3899/jrheum.141307. Epub 2015 Apr 15.

PMID:
25877505
7.

Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.

Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T.

Clin Rheumatol. 2000;19(5):352-9.

PMID:
11055823
8.

Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.

Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, Fujimoto M, Tamaki K.

Rheumatology (Oxford). 2002 Nov;41(11):1268-72.

9.

Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis.

Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J.

Clin Exp Rheumatol. 2013 May-Jun;31(3):428-32. Epub 2013 Mar 13.

PMID:
23485578
10.

Serum KL-6 in adult patients with polymyositis and dermatomyositis.

Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, Tamaki K.

Rheumatology (Oxford). 2000 Jun;39(6):632-6.

11.

[The levels and clinical significance of serum B cell activating factor in Chinese patients with polymyositis or dermatomyositis].

Peng QL, Xie Y, Zhang RF, Shu XM, Wang GC.

Zhonghua Nei Ke Za Zhi. 2012 Mar;51(3):210-3. Chinese.

PMID:
22781895
12.

Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis.

Kubo M, Ihn H, Yamane K, Yazawa N, Kikuchi K, Soma Y, Tamaki K.

Br J Dermatol. 2000 Aug;143(2):392-8.

PMID:
10951151
13.

Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.

Son K, Tomita Y, Shimizu T, Nishinarita S, Sawada S, Horie T.

Intern Med. 2000 Feb;39(2):128-35.

14.

Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.

Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM.

Arthritis Rheum. 1994 Dec;37(12):1744-51.

PMID:
7986220
15.

Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases.

Shen H, Xia L, Lu J.

Cytokine. 2012 Nov;60(2):334-7. doi: 10.1016/j.cyto.2012.07.011. Epub 2012 Aug 3.

PMID:
22863719
16.

Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.

Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, Guo Q, Yang CD, Gu YY, Bao CD, Chen SL.

Clin Rheumatol. 2007 Oct;26(10):1647-54. Epub 2007 Feb 17.

PMID:
17308858
17.

Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia.

Kourakata H, Takada T, Suzuki E, Enomoto K, Saito I, Taguchi Y, Tsukada H, Nakano M, Arakawa M.

Respirology. 1999 Sep;4(3):223-8.

PMID:
10489663
18.

Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.

Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, Uchiyama H, Tamura R, Ida M, Yagi T, Yasuda K, Genma H, Hayakawa H, Chida K, Nakamura H.

J Rheumatol. 2005 Jan;32(1):58-64.

PMID:
15630726
19.

Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis.

Wang DX, Lu X, Zu N, Lin B, Wang LY, Shu XM, Ma L, Wang GC.

Clin Rheumatol. 2012 Dec;31(12):1691-7. doi: 10.1007/s10067-012-2075-4. Epub 2012 Aug 30.

PMID:
22933126
20.

Pulmonary involvement in polymyositis and in dermatomyositis.

Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B.

J Rheumatol. 1998 Jul;25(7):1336-43.

PMID:
9676766
Items per page

Supplemental Content

Write to the Help Desk